Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | arachidonate 5-lipoxygenase | Starlite/ChEMBL | References |
Species | Potential target | Known druggable target/s | Ortholog Group |
---|---|---|---|
Schistosoma mansoni | lipoxygenase | Get druggable targets OG5_127482 | All targets in OG5_127482 |
Schistosoma japonicum | ko:K00461 arachidonate 5-lipoxygenase [EC1.13.11.34], putative | Get druggable targets OG5_127482 | All targets in OG5_127482 |
Schistosoma japonicum | IPR001024,Lipoxygenase, LH2;IPR013819,Lipoxygenase, C-terminal,domain-containing | Get druggable targets OG5_127482 | All targets in OG5_127482 |
Echinococcus granulosus | arachidonate 5 lipoxygenase | Get druggable targets OG5_127482 | All targets in OG5_127482 |
Schistosoma mansoni | lipoxygenase | Get druggable targets OG5_127482 | All targets in OG5_127482 |
Echinococcus multilocularis | arachidonate 5 lipoxygenase | Get druggable targets OG5_127482 | All targets in OG5_127482 |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Mycobacterium tuberculosis | Dihydrofolate reductase DfrA (DHFR) (tetrahydrofolate dehydrogenase) | 1.1327 | 1 | 1 |
Trypanosoma cruzi | dihydrofolate reductase-thymidylate synthase | 0.6765 | 0.5936 | 1 |
Schistosoma mansoni | dihydrofolate reductase | 1.1327 | 1 | 1 |
Onchocerca volvulus | 0.1875 | 0.1581 | 0.5 | |
Toxoplasma gondii | bifunctional dihydrofolate reductase-thymidylate synthase | 0.6765 | 0.5936 | 0.5 |
Chlamydia trachomatis | dihydrofolate reductase | 1.1327 | 1 | 0.5 |
Schistosoma mansoni | lipoxygenase | 0.0142 | 0.0038 | 0.0038 |
Loa Loa (eye worm) | dihydrofolate reductase | 1.1327 | 1 | 1 |
Trichomonas vaginalis | conserved hypothetical protein | 0.0892 | 0.0706 | 0.5 |
Mycobacterium ulcerans | dihydrofolate reductase DfrA | 1.1327 | 1 | 1 |
Echinococcus granulosus | thymidylate synthase | 0.1875 | 0.1581 | 0.1549 |
Echinococcus multilocularis | dihydrofolate reductase | 1.1327 | 1 | 1 |
Trypanosoma brucei | dihydrofolate reductase-thymidylate synthase | 0.6765 | 0.5936 | 0.5 |
Echinococcus multilocularis | thymidylate synthase | 0.1875 | 0.1581 | 0.1549 |
Plasmodium vivax | bifunctional dihydrofolate reductase-thymidylate synthase, putative | 0.6765 | 0.5936 | 0.5 |
Schistosoma mansoni | bifunctional dihydrofolate reductase-thymidylate synthase | 0.1875 | 0.1581 | 0.1581 |
Leishmania major | dihydrofolate reductase-thymidylate synthase | 0.6765 | 0.5936 | 0.5 |
Mycobacterium tuberculosis | Probable thymidylate synthase ThyA (ts) (TSASE) | 0.1875 | 0.1581 | 0.0942 |
Brugia malayi | Dihydrofolate reductase | 1.1327 | 1 | 1 |
Brugia malayi | thymidylate synthase | 0.1875 | 0.1581 | 0.0942 |
Mycobacterium leprae | DIHYDROFOLATE REDUCTASE DFRA (DHFR) (TETRAHYDROFOLATE DEHYDROGENASE) | 1.1327 | 1 | 1 |
Plasmodium falciparum | bifunctional dihydrofolate reductase-thymidylate synthase | 0.6765 | 0.5936 | 0.5 |
Echinococcus granulosus | dihydrofolate reductase | 1.1327 | 1 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IC50 (functional) | = 2.2 uM | Percent inhibition of the compound required for elastase release in stimulated human neutrophils | ChEMBL. | 9871729 |
IC50 (functional) | = 2.2 uM | Percent inhibition of the compound required for elastase release in stimulated human neutrophils | ChEMBL. | 9871729 |
IC50 (binding) | = 6.1 uM | Inhibitory concentration required against 5-lipoxygenase activity in cytosolic fractions of human neutrophils | ChEMBL. | 9871729 |
IC50 (binding) | = 6.1 uM | Inhibitory concentration required against 5-lipoxygenase activity in cytosolic fractions of human neutrophils | ChEMBL. | 9871729 |
IC50 (functional) | = 6.7 uM | Inhibitory concentration required for LTB4 synthesis in stimulated human neutrophils | ChEMBL. | 9871729 |
IC50 (functional) | = 6.7 uM | Inhibitory concentration required for LTB4 synthesis in stimulated human neutrophils | ChEMBL. | 9871729 |
Inhibition (binding) | = 0 % | Inhibition of COX-2 activity in intact human monocytes | ChEMBL. | 9871729 |
Inhibition (binding) | = 0 % | Inhibition of COX-2 activity in intact human monocytes | ChEMBL. | 9871729 |
Inhibition (functional) | = 35.7 % | In vivo inhibition of compound required for migration of neutrophils into the mouse pouch at the dose of 100 nmol/pouch | ChEMBL. | 9871729 |
Inhibition (functional) | = 35.7 % | In vivo inhibition of compound required for migration of neutrophils into the mouse pouch at the dose of 100 nmol/pouch | ChEMBL. | 9871729 |
Inhibition (functional) | = 40 % | In vivo inhibition of compound required to inhibit LTB4 levels in zymogen treated mouse air pouch at a dose of 100 nmol/pouch | ChEMBL. | 9871729 |
Inhibition (functional) | = 40 % | In vivo inhibition of compound required to inhibit LTB4 levels in zymogen treated mouse air pouch at a dose of 100 nmol/pouch | ChEMBL. | 9871729 |
Inhibition (functional) | = 44 % | In vivo inhibition of compound required to inhibit TNF-alpha levels in zymogen treated mouse air pouch at a dose of 100 nmol/pouch | ChEMBL. | 9871729 |
Inhibition (functional) | = 44 % | In vivo inhibition of compound required to inhibit TNF-alpha levels in zymogen treated mouse air pouch at a dose of 100 nmol/pouch | ChEMBL. | 9871729 |
Inhibition (functional) | = 62 % | In vivo inhibition of compound required to inhibit PGE-2 levels in zymogen treated mouse air pouch at a dose of 100 nmol/pouch | ChEMBL. | 9871729 |
Inhibition (functional) | = 62 % | In vivo inhibition of compound required to inhibit PGE-2 levels in zymogen treated mouse air pouch at a dose of 100 nmol/pouch | ChEMBL. | 9871729 |
Species name | Source | Reference | Is orphan |
---|---|---|---|
Homo sapiens | ChEMBL23 | 9871729 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.